Russia's Biocad to compete with Biogen and Roche with new drug for SMA

13 April 2021

Russian drugmaker Biocad says it has completed one of the stages of development of its new drug, which is designed for the treatment of spinal muscular atrophy (SMA), reports The Pharma Letter’s local correspondent.

This is the first drug of such kind produced in Russia. It is known as ANB-4, and the company has been working on its development since the beginning of 2018. The drug has previously shown its efficiency in animals with SMA, and the company is now conducting its clinical and pre-clinical trials already in the short-term.

As an official spokesman of Biocad said in an interview with Forbes Russia magazine, pre-clinical studies of the drug have already begun, while their task was to clarify the optimal dosage of the drug and study its possible toxicity.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK